US10028965 — Use of sustained release dexamethasone in post-cataract surgery inflammation
Method of Use · Assigned to Icon Bioscience Inc · Expires 2034-05-23 · 8y remaining
What this patent protects
This patent protects a treatment regimen using a sustained release liquid formulation of dexamethasone in citrate for anti-inflammatory therapy after cataract surgery.
USPTO Abstract
The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
Drugs covered by this patent
- Decadron (dexamethasone) · Generic (originally Merck)
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2340 |
— | Decadron |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.